GMS infectious diseasesPub Date : 2020-03-26eCollection Date: 2020-01-01DOI: 10.3205/id000053
Klaus-Friedrich Bodmann, Rainer Höhl, Wolfgang Krüger, Beatrice Grabein, Wolfgang Graninger
{"title":"Calculated initial parenteral treatment of bacterial infections: Sepsis.","authors":"Klaus-Friedrich Bodmann, Rainer Höhl, Wolfgang Krüger, Beatrice Grabein, Wolfgang Graninger","doi":"10.3205/id000053","DOIUrl":"10.3205/id000053","url":null,"abstract":"<p><p>This is the eleventh chapter of the guideline \"Calculated initial parenteral treatment of bacterial infections in adults - update 2018\" in the 2<sup>nd</sup> updated version. The German guideline by the Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG) has been translated to address an international audience. Sepsis, defined as a life threatening organ dysfunction caused by a misregulated host response to an infection, is the third leading cause of death in Germany with a lethality rate of 30% to over 50%. An early, effective antimicrobial therapy is, next to infectious source control, the most important causal treatment option. It should be complemented by the mainly supportive measures of general intensive care therapy. Prior antimicrobial therapy, the patient's medical history (e.g. risk factors for multiresistant agents) and small-scale epidemiology are to be considered as part of the therapeutic and practical decisions. A modification of the often needed broad initial calculated combination therapy is desirable. In the future, prompt measurements of plasma concentrations of antiinfectives, especially for the sepsis patient with diverse and partly conflicting pathophysiological changes, will have great importance regarding efficacy, toxicity and resistance development. In order to apply those complex strategies in clinical routine, there is a requirement for a strong interdisciplinary collaboration between the intensive care unit, clinical infectiology, microbiology, and clinical pharmacology, ideally in the framework of a functional antimicrobial stewardship program.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"8 ","pages":"Doc09"},"PeriodicalIF":0.0,"publicationDate":"2020-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37904628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
GMS infectious diseasesPub Date : 2020-03-26eCollection Date: 2020-01-01DOI: 10.3205/id000048
Béatrice Grabein, Michael Ebenhoch, Ernst Kühnen, Florian Thalhammer
{"title":"Calculated parenteral initial treatment of bacterial infections: Infections with multi-resistant Gram-negative rods - ESBL producers, carbapenemase-producing Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii.","authors":"Béatrice Grabein, Michael Ebenhoch, Ernst Kühnen, Florian Thalhammer","doi":"10.3205/id000048","DOIUrl":"10.3205/id000048","url":null,"abstract":"<p><p>This is the sixteenth chapter of the guideline \"Calculated initial parenteral treatment of bacterial infections in adults - update 2018\" in the 2<sup>nd</sup> updated version. The German guideline by the Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG) has been translated to address an international audience. Infections due to multiresistant Gram-negative rods are challenging. In this chapter recommendations for targeted therapy for infections caused by ESBL-producing Enterobacteriaceae, carbapenemase-producing Enterobacteriaceae and carbapenem-resistant <i>Acinetobacter baumannii</i> are given, based on the limited available evidence.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"8 ","pages":"Doc04"},"PeriodicalIF":0.0,"publicationDate":"2020-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37905720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
GMS infectious diseasesPub Date : 2020-03-26eCollection Date: 2020-01-01DOI: 10.3205/id000058
Bernhard Olzowy, Bilal Al-Nawas, Miriam Havel, Julia Karbach, Rainer Müller
{"title":"Calculated parenteral initial treatment of bacterial infections: Infections in the ear, nose, throat and mouth and jaw area.","authors":"Bernhard Olzowy, Bilal Al-Nawas, Miriam Havel, Julia Karbach, Rainer Müller","doi":"10.3205/id000058","DOIUrl":"10.3205/id000058","url":null,"abstract":"<p><p>This is the sixth chapter of the guideline \"Calculated initial parenteral treatment of bacterial infections in adults - update 2018\" in the 2<sup>nd</sup> updated version. The German guideline by the Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG) has been translated to address an international audience. The chapter deals with the antibacterial treatment of more severe infections of the ear, the nose, the throat and the maxillofacial region, including odontogenic and salivary gland infections.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"8 ","pages":"Doc14"},"PeriodicalIF":0.0,"publicationDate":"2020-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37904553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
GMS infectious diseasesPub Date : 2020-03-26eCollection Date: 2020-01-01DOI: 10.3205/id000062
Michael Kresken, Béatrice Grabein, Karsten Becker, Eberhard Straube, Thomas A Wichelhaus, Birgit Willinger
{"title":"Calculated parenteral initial treatment of bacterial infections: Microbiology.","authors":"Michael Kresken, Béatrice Grabein, Karsten Becker, Eberhard Straube, Thomas A Wichelhaus, Birgit Willinger","doi":"10.3205/id000062","DOIUrl":"10.3205/id000062","url":null,"abstract":"<p><p>This is the second chapter of the guideline \"Calculated initial parenteral treatment of bacterial infections in adults - update 2018\" in the 2<sup>nd</sup> updated version. The German guideline by the Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG) has been translated to address an international audience. Preliminary microbiological findings regarding the patient and their immediate environment are crucial for the calculation of treatment with antibiotics in each case, as well as the resistance situation of the ward on which the patient is being cared for. If such data is not available, regional or supra-regional data can be used as a fallback. This chapter describes the methods of susceptibility testing, informs about the resistance situation in Germany and describes the main resistance mechanisms of bacterial pathogens against antibiotics. Further, the chapter informs about collateral damage of antibiotics as well as medical measures against increasing resistance.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"8 ","pages":"Doc18"},"PeriodicalIF":0.0,"publicationDate":"2020-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37904556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
GMS infectious diseasesPub Date : 2020-03-12eCollection Date: 2020-01-01DOI: 10.3205/id000045
Gerd E Gross, Lisa Eisert, Hans Wilhelm Doerr, Helmut Fickenscher, Markus Knuf, Philip Maier, Matthias Maschke, Rainer Müller, Uwe Pleyer, Michael Schäfer, Cord Sunderkötter, Ricardo N Werner, Peter Wutzler, Alexander Nast
{"title":"[S2k guideline for the diagnosis and therapy of zoster and post-zoster neuralgia].","authors":"Gerd E Gross, Lisa Eisert, Hans Wilhelm Doerr, Helmut Fickenscher, Markus Knuf, Philip Maier, Matthias Maschke, Rainer Müller, Uwe Pleyer, Michael Schäfer, Cord Sunderkötter, Ricardo N Werner, Peter Wutzler, Alexander Nast","doi":"10.3205/id000045","DOIUrl":"https://doi.org/10.3205/id000045","url":null,"abstract":"<p><p>This guideline is aimed at registrars and consultants in dermatology, ophthalmology, ENT, pediatrics, neurology, virology as well as infectiology, anaesthesia and generell medicine as well as policymakers and payers and purchasers of care. It was developed by dermatologists, virologists, ophthalmologists, ENT physicians, neurologists, pediatrician and anesthetists using a formal consensus process (S2k).The guideline provides an overview of clinical and molecular diagnostics as well as antigen detection, antibody culture and viral culture. Diagnostic special situations and complicated courses of the disease are also considered. The antiviral therapy of zoster and postzoster neuralgia is presented in general and for special situations. Detailed information on the treatment of pain is mentioned and presented in an overview. Likewise, the local therapeutic measures are discussed.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"8 ","pages":"Doc01"},"PeriodicalIF":0.0,"publicationDate":"2020-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37905718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. C. Buerfent, J. Ajendra, W. Stamminger, Fabian Gondorf, A. Hoerauf, M. Hübner
{"title":"TGFβ depletion does neither modulate acute E. coli-induced inflammatory immune responses nor impair the protective effect by chronic filarial infection","authors":"B. C. Buerfent, J. Ajendra, W. Stamminger, Fabian Gondorf, A. Hoerauf, M. Hübner","doi":"10.3205/id000044","DOIUrl":"https://doi.org/10.3205/id000044","url":null,"abstract":"TGFβ is an anti-inflammatory molecule that suppresses pro-inflammatory immune responses. Previously, we demonstrated that chronic filarial infection has a beneficial impact on Escherichia coli-induced sepsis. In the present study, we investigated whether this protective effect is dependent on TGFβ signaling and whether depletion of TGFβ before E. coli challenge alters the early course of sepsis per se. In vivo depletion of TGFβ before E. coli challenge did not alter levels of pro-inflammatory cytokines/chemokines and did neither increase the bacterial burden nor worsen E. coli-induced hypothermia six hours post E. coli challenge. Similarly, in the co-infection model, despite TGFβ depletion, mice infected with the filarial nematode Litomosoides sigmodontis exhibited milder E. coli-induced hypothermia, reduced bacterial load and pro-inflammatory immune responses. Thus, we conclude that TGFβ is not essentially modulating the initial pro-inflammatory phase during sepsis and that the protective effect of a chronic filarial infection against sepsis is independent of TGFβ signaling.","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44902196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Wilke, K. Worf, Birgit Preisendörfer, W. Heinlein, T. Kast, K. Bodmann
{"title":"Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment – a health economic analysis using German DRG data","authors":"M. Wilke, K. Worf, Birgit Preisendörfer, W. Heinlein, T. Kast, K. Bodmann","doi":"10.3205/id000043","DOIUrl":"https://doi.org/10.3205/id000043","url":null,"abstract":"Complicated infections such as osteomyelitis, skin and soft tissue infections or endocarditis often require antibiotic therapies that can last up to several weeks. The prolonged hospital length of stay (LOS) leads to a dramatic increase in costs. Single-dose intravenous Dalbavancin is a novel antimicrobial agent for the treatment of acute bacterial skin, skin structure and soft tissue infections (ABSSSI) that allows an earlier discharge of patients, resulting in potential savings. Joint, bone and prostheses infections (JBPI) are also related with long LOS. The aim of this study is to determine the economic effects of single-dose intravenous Dalbavancin in suitable patients with Methicillin-resistant Staphylococcus aureus infections in Germany. For this purpose, an analysis with real-world patient treatment data was performed, which was subsequently validated in a large German hospital. In total, ABSSSI patients with MRSA infections could stay 6.45 days shorter and 2,865 € could be saved while JBPI patients could be discharged eventually 10.6 days earlier and 3,909 € could be saved. Single-dose intravenous Dalbavancin is thus an option for patients with ABSSSI and JBPI who are eligible for discharge.","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47778085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rhodotorula spp. in the gut – foe or friend?","authors":"H. Hof","doi":"10.3205/id000042","DOIUrl":"https://doi.org/10.3205/id000042","url":null,"abstract":"Rhodotorula spp. belong to the basidiomyceteous fungi. They are widespread in the environment. Transmission to humans occur mainly through air and food. Intestinal colonization is rather common, but an overgrowth is normally suppressed, since their optimal growth temperature is exceeded in the body. A massive presence in the gut indicates a disturbance of the balance of the microbial flora due to different causes. One particular reason will be the treatment with azoles because this will create an advantage for these azole resistant fungi. First of all, the finding of increased numbers of Rhodotorula in stool specimen is not alarming. In contrast, the colonized human will profit from such a situation since these fungi produce a lot of useful nutrients such as proteins, lipids, folate, and carotinoids. Furthermore, a probiotic effect due to regulation of multiplication of pathogenic bacteria and by neutralizing or destroying their toxins can be anticipated. On the other hand, their massive presence may increase the risk of fungemia and ensuing organ infections especially when the host defense system is hampered. Indeed, Rhodotorula spp. range among the emerging fungal pathogens in the compromised host. However, it can be doubted whether all these opportunistic infections reported originate primarily from the gut.","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49061327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
GMS infectious diseasesPub Date : 2019-02-19eCollection Date: 2019-01-01DOI: 10.3205/id000041
Susanne Deininger, Nele Wellinghausen
{"title":"Evaluation of a new combined Western and line blot assay (EUROLINE-WB) for diagnosis and species identification of Echinococcus infection in humans.","authors":"Susanne Deininger, Nele Wellinghausen","doi":"10.3205/id000041","DOIUrl":"https://doi.org/10.3205/id000041","url":null,"abstract":"<p><p>Serological detection of echinococcosis is crucial for diagnosis and management. We evaluated the new blot assay Euroline-WB (ELB, Euroimmun) which consists of a Western blot with <i>Echinococcus multilocularis (E.m.)</i> vesicle antigens and a line blot part with recombinant antigens from <i>E. granulosus</i> (<i>E.g.</i>, genus-specific EgAgB) and <i>E.m.</i> (species-specific Em18 and Em95), in comparison to a commercial Western Blot (EWB, LDBio) for detection and species differentiation of echinococcosis within routine laboratory diagnostics. Thirty-five serum samples from 35 patients classified according to a standardized classification were included in the analysis. Out of 24 cases of proven and probable infection with <i>E.m.</i> or <i>E.g.</i> 16 (66.7%) and 15 (62.5%) were correctly identified on species level by EWB and ELB, respectively. False <i>Echinococcus</i> species were assigned in two cases by EWB but none by ELB. Negative blot results in patients with proven infections were noticed in 8.3% (ELB) compared to 4.2% (EWB), but were limited to patients with antiparasitic therapy or post-surgery indicating a treatment-induced loss of antibody activity. Thus, identification of <i>Echinococcus</i> infection at least on the genus level was possible in 23/24 (95.8%) and 19/24 (79.2%) of patients by EWB and ELB (or 22/24 patients (91.7%) including borderline results of ELB), respectively. Recombinant Em18 and Em95 were highly specific for detection of <i>E.m.</i> infection but differed in sensitivity (Em18 56% and 80 %, and Em95 22% and 20% in proven and probable infections, respectively). Advantages of ELB are the standardized analysis of the banding pattern by EUROLineScan software and a faster turn-around-time.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"7 ","pages":"Doc01"},"PeriodicalIF":0.0,"publicationDate":"2019-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3205/id000041","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37161183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}